Medical Big Data

PicnicHealth & Komodo Health to Utilize Real-World Patient Data

Collaboration enables PicnicHealth to unlock rich new insights about complex diseases and treatment outcomes in its Research Platform

PicnicHealth and Komodo Health today announced a partnership to support real-world evidence research programs for complex illnesses like multiple sclerosis and hemophilia. With this partnership, PicnicHealth will enrich its database of de-identified patient medical records with data from Komodo’s Healthcare Map™. The combined breadth and depth of real-world patient data will help support research efforts to close gaps in care, address unmet patient needs, and streamline clinical development efforts to deliver life-saving therapies to appropriate patients.

By integrating PicnicHealth’s data with Komodo’s Healthcare Map, PicnicHealth’s Research Platform will offer differentiated insights on complex therapeutic areas that may have variable impacts on population subsets. For heterogeneous diseases like multiple sclerosis, controlled clinical research settings are limited in the scope of insights they provide. At the same time, real-world studies have historically faced challenges in gathering the necessary data in these therapeutic areas where patients are moving between providers and healthcare organizations, which each use different systems of record.

To address these shortcomings, PicnicHealth is tapping Komodo’s Sentinel platform to gather journeys of thousands of patients with a given condition into a single research database. The series of initiatives is already generating insights that layer demographic and geographic distributions of patients with analyses of patient journeys and care patterns to unlock new learnings about patients with previously difficult-to-study diseases.

“Komodo Health and PicnicHealth share a mission to utilize health data to better understand disease,” said Noga Leviner, CEO and co-founder of PicnicHealth. “Through this collaboration, we will pool our combined capabilities to work toward a deeper understanding of patient histories, treatment patterns, and therapeutic outcomes in the real world. We are excited to be tapping into the breadth and depth of Komodo’s Healthcare Map to drive groundbreaking clinical research that can ultimately benefit patients suffering from complex diseases.”

PicnicHealth provides patients ownership of their medical data by aggregating each patient’s medical records into a comprehensive and accessible dashboard. In July 2020, the company launched the PicnicHealth Research Platform, a real-world evidence based biomedical research program to explore the progression of diseases, including multiple sclerosis, sickle cell disease, and hemophilia, among others.

Komodo Health has created the new standard for real-world data and analytics by pairing the industry’s most complete view of patient encounters with enterprise cloud technologies that connect the dots between individual patient journeys and large-scale health outcomes. Komodo’s Healthcare Map unlocks a deeper understanding of the healthcare experiences of more than 325 million patients. Additionally, its Sentinel platform allows clinical, commercial, and HEOR Life Sciences teams to integrate data from the Healthcare Map with their own proprietary datasets to track detailed patient behaviors and treatment patterns that unlock critical strategic insights.

“PicnicHealth shares our conviction that reliable medical data has the power to unearth deeper insight into disease trends, supplement clinical trials, and unlock the potential of new treatments,” said Arif Nathoo, MD, CEO and co-founder of Komodo Health. “We see that researchers need access to a longitudinal view of healthcare to understand how complex diseases work in the real world. Together, Komodo and PicnicHealth are creating a full picture to support patient-centered innovation and care.”

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.

Related posts

Healthtech Brii Biosciences Closes US$155M Round

Business Wire

Sema4 and CM Life Sciences File the Schedule-14A Proxy Statement

Business Wire

ASCO 2024 study uses ConcertAI Oncology Dataset to find earlier treatment

PR Newswire